BEIJING, June 18 (Xinhua) -- Immunotech Biopharm digital cell medicine industrialization base officially starts construction in Beijing Economic-Technological Development Area Thursday, reported Beijing Daily on Friday.
The project attracts an investment of 1.2 billion yuan and is expected to be completed and put into production in 2023. After completion, it will be the first Chinese cell medicine industrialization base as well as the world's largest industrialization base.
The construction content of the project encompasses cell medicine transformation research center, cell medicine preparation center and standardized, integrated cellular immune R&D complex. As the first domestic immune cell production and preparation industrial base that meets the requirements of GMP (Good Manufacturing Practice), it is estimated to produce annual output value of about 3.5 billion yuan.
The project is of milestone significance for the rapid advancement of the industrialization and commercialization of bio-cell medicine, and will build an industrialization base combining industry, technology and medical care.
(Edited by Bao Nuomin with Xinhua Silk Road, baonuomin@xinhua.org)
A single purchase
